KR20230159380A - 고지혈증 또는 혼합형 이상지혈증을 앓고 있는 스타틴불내성 환자에서 사용하기 위한 오비세트라피브 및 에제티미브의 조합 요법 - Google Patents

고지혈증 또는 혼합형 이상지혈증을 앓고 있는 스타틴불내성 환자에서 사용하기 위한 오비세트라피브 및 에제티미브의 조합 요법 Download PDF

Info

Publication number
KR20230159380A
KR20230159380A KR1020237028087A KR20237028087A KR20230159380A KR 20230159380 A KR20230159380 A KR 20230159380A KR 1020237028087 A KR1020237028087 A KR 1020237028087A KR 20237028087 A KR20237028087 A KR 20237028087A KR 20230159380 A KR20230159380 A KR 20230159380A
Authority
KR
South Korea
Prior art keywords
obisetrapib
ezetimibe
combination
ldl
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237028087A
Other languages
English (en)
Korean (ko)
Inventor
요하네스 야콥 피터 카스텔레인
마르크 디트마르스
미카엘 하르비 다비드슨
Original Assignee
뉴암스테르담 파마 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴암스테르담 파마 비.브이. filed Critical 뉴암스테르담 파마 비.브이.
Publication of KR20230159380A publication Critical patent/KR20230159380A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237028087A 2021-02-18 2022-02-18 고지혈증 또는 혼합형 이상지혈증을 앓고 있는 스타틴불내성 환자에서 사용하기 위한 오비세트라피브 및 에제티미브의 조합 요법 Pending KR20230159380A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2021050109 2021-02-18
NLPCT/NL2021/050109 2021-02-18
PCT/NL2022/050083 WO2022177428A1 (en) 2021-02-18 2022-02-18 Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia

Publications (1)

Publication Number Publication Date
KR20230159380A true KR20230159380A (ko) 2023-11-21

Family

ID=74844966

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237028087A Pending KR20230159380A (ko) 2021-02-18 2022-02-18 고지혈증 또는 혼합형 이상지혈증을 앓고 있는 스타틴불내성 환자에서 사용하기 위한 오비세트라피브 및 에제티미브의 조합 요법

Country Status (11)

Country Link
US (1) US20240189311A1 (https=)
EP (1) EP4294387A1 (https=)
JP (1) JP2024507810A (https=)
KR (1) KR20230159380A (https=)
CN (1) CN117042770A (https=)
AU (1) AU2022223224A1 (https=)
BR (1) BR112023016682A2 (https=)
CA (1) CA3210033A1 (https=)
IL (1) IL304544A (https=)
MX (1) MX2023009613A (https=)
WO (1) WO2022177428A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12006305B2 (en) 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
WO2024165395A1 (en) * 2023-02-07 2024-08-15 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025146445A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Pharmaceutical compositions of obicetrapib and ezetimibe
WO2025146262A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies
WO2025146446A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Pharmaceutical compositions of obicetrapib
WO2025147235A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Fixed dose combination composition of obicetrapib and ezetimibe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
MX369471B (es) * 2014-02-05 2019-11-08 Dezima Pharma B V Inhibidor de proteina de transferencia del ester de colesterilo (cetp) y composiciones farmaceuticas que comprenden el inhibidor para uso en el tratamiento o prevencion de enfermedades cardiovasculares.
WO2017023166A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor
US12006305B2 (en) * 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
JP2025527686A (ja) * 2022-08-22 2025-08-22 ニューアムステルダム・ファルマ・ベー・フェー オビセトラピブ及びエゼチミブ併用治療及び固定用量医薬組成物

Also Published As

Publication number Publication date
JP2024507810A (ja) 2024-02-21
AU2022223224A1 (en) 2023-08-24
CN117042770A (zh) 2023-11-10
IL304544A (en) 2023-09-01
MX2023009613A (es) 2023-11-09
WO2022177428A1 (en) 2022-08-25
BR112023016682A2 (pt) 2023-11-14
EP4294387A1 (en) 2023-12-27
US20240189311A1 (en) 2024-06-13
CA3210033A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
US20240189311A1 (en) Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia
BG66009B1 (bg) Използване на розувастатин (zd-4522) за лечение на хетерозиготна наследствена хиперхолестеролемия
JP2014521659A (ja) ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
JP7304913B2 (ja) コレステリルエステル転送タンパク質阻害剤及びＨＭＧ ＣｏＡ還元酵素阻害剤を含む医薬組成物及び治療併用剤
EP1185274A1 (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
DE19858789A1 (de) Kombination von Cerivastatin und Fibraten
JP2024527023A (ja) Ｈｉｓ低応答者の治療
JP6202633B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
KR20020086749A (ko) 베타 블록커 및 콜레스테롤 저하제의 신규한 조합물
WO2022115576A9 (en) Treatment of raynaud's disease
KR100539066B1 (ko) 비정상적 지질대사-유래 질환치료에 유용한 스타틴과알카노일 ｌ-카르니틴 함유 약제 조성물
JP2015512948A (ja) ハロフェナートまたはハロフェン酸および抗炎症剤を用いる痛風に罹っている患者の高尿酸血症の治療方法
WO2025059594A9 (en) METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)
JPWO2005074909A1 (ja) 併用医薬
JP2021530569A (ja) 自閉症を処置するための組成物および方法
JP2021530568A (ja) 自閉症を処置するための組成物および方法
JP2024532129A5 (https=)
JP2017039762A (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
US20030191177A1 (en) Fomulation
HK40097427A (en) Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa reductase inhibitors
HK40051810A (en) Pharmaceutical compositions and therapeutic combinations comprising cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors
GB2540163A (en) Combination therapy for treating multiple sclerosis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230818

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250214

Comment text: Request for Examination of Application